loading page

Association of metformin with the mortality and incidence of cardiovascular events in patients with pre-existing cardiovascular diseases
  • +9
  • Tian Li,
  • Rui Providencia,
  • Wenhua Jiang,
  • Nan Mu,
  • Yishi Wang,
  • Xiaokang Li,
  • Yue Yin,
  • Manling Liu,
  • Lu Yu,
  • Chunhu Gu,
  • Alex Chia Yu Chang,
  • Heng Ma
Tian Li
Fourth Military Medical University

Corresponding Author:[email protected]

Author Profile
Rui Providencia
Saint Bartholomew's Hospital Barts Heart Centre
Author Profile
Wenhua Jiang
Fourth Military Medical University
Author Profile
Nan Mu
Fourth Military Medical University
Author Profile
Yishi Wang
Fourth Military Medical University
Author Profile
Xiaokang Li
Fourth Military Medical University
Author Profile
Yue Yin
Fourth Military Medical University
Author Profile
Manling Liu
Fourth Military Medical University
Author Profile
Lu Yu
Fourth Military Medical University
Author Profile
Chunhu Gu
Fourth Military Medical University
Author Profile
Alex Chia Yu Chang
Shanghai Jiao Tong University
Author Profile
Heng Ma
Fourth Military Medical University
Author Profile

Abstract

Background and Purpose Whereas whether metformin reduce all-cause, cardiovascular mortality, and incidence of cardiovascular events in patients with cardiac diseases remains inconclusive. Experimental Approach PubMed and Embase were searched up to May 2020 with a registration in PROSPERO (CRD42020189905) were collected. This article includes randomized controlled trials (RCT) and cohort studies. Hazard ratio (HR) with 95% CI was pooled across various trials by a random-effects model. Risk of bias was accounted as per Cochrane and Newcastle-Ottawa Scale (NOS) guidelines. Key Results This article enrolled 48 articles (1999-2020) for qualitative synthesis and identified 26 articles (33 studies in total, 61,704 patients) for final quantitative synthesis. Compared with non-metformin control, metformin is associated with reduced all-cause mortality (HR: 0.90; 95% CI: 0.83, 0.98; P = 0.01), cardiovascular mortality (HR: 0.89; 95% CI: 0.85, 0.94; P < 0.0001), incidence of coronary revascularization (HR: 0.79; 95% CI: 0.64, 0.98; P = 0.03), and heart failure (HR: 0.90; 95% CI: 0.87, 0.94; P < 0.0001) in patients with cardiac diseases, whereas metformin is not associated with reduced incidence of myocardial infarction (HR: 0.97; 95% CI: 0.80, 1.17; P = 0.73), angina (HR: 0.29; 95% CI: 0.04, 2.35; P = 0.25), and stroke (HR: 0.95; 95% CI: 0.78, 1.16; P = 0.59). Conclusion and Implications Metformin reduces all-cause mortality, cardiovascular mortality, incidence of coronary revascularization, and heart failure of patients with cardiac diseases, whereas metformin is not associated with reduced incidence of myocardial infarction, angina, and stroke.
Feb 2022Published in Drugs volume 82 issue 3 on pages 311-322. 10.1007/s40265-021-01665-0